11 research outputs found

    Blockade of IFN-gamma does not affect the arthritogenicity of T cells generated during the induction of adjuvant arthritis but exacerbates the polyarthritis produced by adoptive transfer of arthritogenic effector cells

    No full text
    © 2007 Australasian Society for ImmunologyIFN- production is prominent in some models of autoimmune disease, including adjuvant arthritis (AA), but the role of IFN- in the pathogenesis of these diseases is uncertain. Experimental manipulation (administration of cytokine, blocking cytokine action with specific antibody, disruption of genes encoding the cytokine or its receptor) has revealed both pro- and anti-inflammatory effects, depending on the nature of the manipulation and the timing of the treatment. We examined separately the effects of cytokine blockade during the afferent and efferent phases of AA in Dark Agouti rats, using an adoptive transfer system. Effects of IFN- on the efferent phase were investigated by treating recipients with mAb DB-1, which blocks the activity of rat IFN-. When treatment was commenced before cell transfer, the resulting polyarthritis was more severe than in controls treated with normal IgG. Commencing treatment after the adoptively transferred disease had become established caused neither amelioration nor exacerbation, but did cause some delay in resolution. In contrast, treatment of donors did not appear to affect the generation of arthritogenic cells. The main effect of IFN- appears to be modulation of the arthritogenicity of the migratory effector T cells that can transfer AA

    Drugs that Target Sympathetic–Immune Pathways for Treatment of Autoimmune Diseases

    No full text

    Pyelonephritis und chronische interstitielle Nephritis

    No full text
    corecore